Matches in Nanopublications for { ?s ?p "[The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP1233252.RAR1i9YvN_zRspal1xi19epzEyFy_0GwJYg_uZphM5CBM130_assertion description "[The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233252.RAR1i9YvN_zRspal1xi19epzEyFy_0GwJYg_uZphM5CBM130_provenance.
- NP1233247.RAu-HvXnXKCS1mQ-YGdkprKQv0hgMMdL9qoI4intKC-m4130_assertion description "[The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233247.RAu-HvXnXKCS1mQ-YGdkprKQv0hgMMdL9qoI4intKC-m4130_provenance.
- NP1233248.RAtwTBkllVr5UtJ-sy3RlfgEOCXsbVBE4buVjqzPhQipM130_assertion description "[The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233248.RAtwTBkllVr5UtJ-sy3RlfgEOCXsbVBE4buVjqzPhQipM130_provenance.
- NP1233249.RAJOqdi-MAkk4sCKuwqIllz7ApCFUBwtF8i0Pq9mfakgc130_assertion description "[The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233249.RAJOqdi-MAkk4sCKuwqIllz7ApCFUBwtF8i0Pq9mfakgc130_provenance.
- NP1233250.RAKXuTn3rlvH0_7kyIaLDCM1BTbgRN-BVUi57v0BKjSdI130_assertion description "[The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233250.RAKXuTn3rlvH0_7kyIaLDCM1BTbgRN-BVUi57v0BKjSdI130_provenance.
- NP1233251.RAEb5MWJ2hKRtm1MFhZkR_mWz6lDLzfM5rFiyErrDktNY130_assertion description "[The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233251.RAEb5MWJ2hKRtm1MFhZkR_mWz6lDLzfM5rFiyErrDktNY130_provenance.
- NP1233253.RAJa2LPkKM56xYd74LCNvMi8iNrCTq5tdopUIWezVnqCU130_assertion description "[The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233253.RAJa2LPkKM56xYd74LCNvMi8iNrCTq5tdopUIWezVnqCU130_provenance.
- NP1233254.RAE3k7yYND35Hf8Y8YzhFUMt8Aks3Xbc2sDD0Tu02wrHc130_assertion description "[The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233254.RAE3k7yYND35Hf8Y8YzhFUMt8Aks3Xbc2sDD0Tu02wrHc130_provenance.